Unique property of some synthetic retinoids: activation of the aryl hydrocarbon receptor pathway.
Potential pharmacological applications in the areas of oncology, dermatology, diabetes, and atherosclerosis of synthetic analogs of retinoic acid that target a specific nuclear receptor and/or biological response have generated great interest in the development of new retinoid and rexinoid drugs. The pan-retinoic acid receptor antagonist AGN 193109 has been previously reported to elevate CYP1A1 levels, implicating the aryl hydrocarbon receptor (AhR) as an additional target for this retinoid. AhR is a cytosolic ligand-dependent transcription factor that, in conjunction with the AhR nuclear translocator (Arnt), binds to dioxin response elements (DREs) located in the promoter region of target genes, such as CYP1A1, and induces their transcription. The purpose of these studies was to determine whether additional synthetic retinoids were capable of elevating CYP1A1 levels and to examine the mechanism of this increase in CYP1A. Two additional retinoids, AGN 190730 and AGN 192837, were found to be potent inducers of DRE-driven transcriptional activity; AGN 190730 was the most potent. Moreover, electrophoretic mobility-shift assays demonstrate that AGN 190730 can transform AhR into its active DNA recognition form. In addition, trypsin digestion of AGN 190730-treated AhR reveals a conformational change in the protein similar to the conformational change of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-bound AhR. Finally, competitive binding studies demonstrate that AGN 190730 can inhibit the binding of TCDD to AhR. The sum of the data demonstrates that some synthetic retinoids in addition to activating the retinoic acid receptor/retinoid X receptor pathway are capable of binding to AhR and activating the AhR/Arnt pathway.
Gambone
Carlo J
CJ
Department of Biochemistry, Temple University School of Medicine, Philadelphia, Pennsylvania 19140, USA.
Hutcheson
Juliet M
JM
Gabriel
Jerome L
JL
Beard
Richard L
RL
Chandraratna
Roshantha A S
RA
Soprano
Kenneth J
KJ
Soprano
Dianne Robert
DR
D000218:Adamantane / Q000031:analogs & derivatives / Q000494:pharmacology; D001667:Binding, Competitive; D015153:Blotting, Western; D019363:Cytochrome P-450 CYP1A1 / Q000235:genetics / Q000378:metabolism*; D004247:DNA / Q000378:metabolism; D004789:Enzyme Activation; D006801:Humans; D009281:Naphthalenes / Q000494:pharmacology; D011401:Promoter Regions, Genetic / Q000187:drug effects; D011487:Protein Conformation; D018336:Receptors, Aryl Hydrocarbon / Q000737:chemistry / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D012176:Retinoids / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D015533:Transcriptional Activation / Q000187:drug effects*; D014407:Tumor Cells, Cultured
C446027:AGN 190730; C446028:AGN 192837; D009281:Naphthalenes; D018336:Receptors, Aryl Hydrocarbon; D012176:Retinoids; D004247:DNA; D019363:Cytochrome P-450 CYP1A1; D000218:Adamantane